Investors

2023 Investor Webinar

Company Overview

AXIM Biotechnologies (OTC: AXIM) is an international healthcare solutions company targeting ocular biomarkers. AXIM Eye is working with two highly specialized Point-of-Care (POC) lab testing solutions designed specifically to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis.

Most Recent Shareholder Letter

Email Alerts

Stay informed and receive company updates straight to your inbox

Recent News

AXIM Biotechnologies CEO Issues Letter to Shareholders

Summary: In 2022, AXIM® finalized optimization of its R&D and manufacturing infrastructure to be used in its diagnostic program AXIM will continue to generate revenue from its two FDA-cleared dry eye disease (DED) diagnostic tests through commercialization partner...

Latest Annual Filing

Fiscal Year Ended Dec 31, 2021

Investor Contact Information

Company

AXIM Biotechnologies, Inc.
6191 Cornerstone Court, E., Suite 114,    San Diego, CA 92121
T: +1 858 923-4422

Investor Relations

Transfer Agent

Action Stock Transfer Corporation
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
T: 801-274-1088
info@actionstocktransfer.com
www.actionstocktransfer.com